Desenvolvimento e validação de método analítico para determinação de brinzolamida em suspensão oftálmica 1%

Abstract

Glaucoma is an optic neuropathy caused by multiple factors, characterized by progressive damage to the optic nerve and increased intraocular pressure, its main risk factor. Brinzolamide is a sulfonamide nonbacteriostatic derivative inhibitor of carbonic anhydrase II, which decreases the intraocular pressure by reducing aqueous humor formation. A stability-indicating HPLC method for the determination of brinzolamide in ophthalmic solution was developed and validated. Chromatographic analysis were performed in Phemomenex® C18 column (150x4.6 mm, particle size 5 μm). The mobile phase was composed of acetonitrile and 25 mM monobasic potassium phosphate buffer adjusted to pH 5.8 (40:60; v/v), flow rate of 1.0 mL/min and injection volume of 20 μL. The method was simple, rapid, specific, linear, precise, accurate and robust, suitable for use in routine quality control.